Bridged cyclic amino acids as pharmaceutical agents
AssigneeWarner-Lambert Company
InventorsDavid Christopher Horwell, Justin S. Bryans, Clare O. Kneen, Andrew I. Morrell, Giles S. Ratcliffe
Life of this patent
Estimating the term…
Abstract
Bridged cyclic amino acids of formula ##STR1## are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain and neuropathological disorders. Processes for the preparation and intermediates useful in the preparation are also disclosed.
Claims24
A compound of formula ##STR22## a pharmaceutically acceptable salt thereof or a prodrug thereof wherein A is a bridged ring selected from ##STR23## wherein R.sub.1 and R.sub.2 are each independently selected from hydrogen and methyl;
- R.sub.3 and R.sub.4 are each independently selected from hydrogen or methyl;
- n is an integer of from 1 to 4;
- and
- m is an integer of from 0 to 2.
A compound of formula ##STR24## or a pharmaceutically acceptable salt thereof wherein A is a bridged ring selected from ##STR25## wherein n is an integer of from 1 to 4;
- and
- m is an integer of from 0 to 2.
A compound of formula I ##STR26## or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein A is ##STR27## wherein n is an integer of from 1 to 4, and m is an integer of from 0 to 2.
A compound of formula I ##STR29## or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein A is ##STR30## wherein n is an integer of from 1 to 4.
A compound of formula I ##STR31## or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein A is ##STR32## wherein n is an integer of from 1 to 4.
A compound of formula I ##STR33## or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein A is ##STR34##
A method for treating epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain and neuropathological disorders comprising administering a therapeutically effective amount of a compound of formula ##STR35## a pharmaceutically acceptable salt thereof or a prodrug thereof wherein A is a bridged ring selected from ##STR36## wherein R.sub.1 and R.sub.2 are each independently selected from hydrogen and methyl;
- R.sub.3 and R.sub.4 are each independently selected from hydrogen and methyl;
- n is an integer of from 1 to 4;
- and
- m is an integer of from 0 to 2 to a mammal in need of said treatment.
A compound which is 7-aminomethyl-bicyclo[2.2.1]hept-7-yl-acetic acid.
A compound which is bicyclic [3.3.1]nonane gabapentin.
Dependencies are inferred from the claim text.